康龙化成(300759) - 2025 Q2 - 季度业绩预告

WuXi AppTec 2025 Half-Year Performance Forecast WuXi AppTec provides its preliminary financial outlook for the first half of 2025, detailing expected changes in key performance indicators Current Period Performance Forecast The company anticipates year-over-year growth in H1 2025 operating revenue, net profit excluding non-recurring gains/losses, and adjusted non-IFRS net profit, while net profit attributable to shareholders is expected to decline by 36%-39% due to significant non-recurring gains in the prior year Key Financial Indicators for H1 2025 Performance Forecast | Item | Current Period (2025H1) | Prior Period (2024H1) | Change | | :--- | :--- | :--- | :--- | | Operating Revenue | RMB 6,333.0436 million - RMB 6,501.1775 million | RMB 5,604.4634 million | Growth 13%–16% | | Net Profit Attributable to Shareholders | RMB 679.1758 million - RMB 712.5779 million | RMB 1,113.4030 million | Decline 36%–39% | | Net Profit Excluding Non-Recurring Gains/Losses | RMB 624.2831 million - RMB 647.5772 million | RMB 465.8829 million | Growth 34%–39% | | Adjusted Non-IFRS Net Profit | RMB 731.6822 million - RMB 766.1955 million | RMB 690.2662 million | Growth 6%–11% | | Basic Earnings Per Share | RMB 0.3858 - RMB 0.4048/share | RMB 0.6282/share | - | - The company estimates H1 2025 non-recurring gains/losses attributable to shareholders to be approximately RMB 60 million to RMB 70 million, primarily comprising government subsidies, fair value changes in financial assets, and wealth management product gains/losses[7] - The company uses adjusted non-IFRS net profit as a supplementary financial metric, excluding the impact of share-based payments, exchange gains/losses, equity investment gains/losses, convertible bond-related gains/losses, and other incidental or non-operating items, to better assess core business performance[8] Communication with Accounting Firm This performance forecast has not been audited or pre-audited by an accounting firm - This performance forecast has not been audited or pre-audited by an accounting firm[10] Explanation of Performance Changes Performance changes are primarily driven by robust core business growth and a significant year-over-year decrease in non-recurring gains/losses, impacting net profit attributable to shareholders - The company steadfastly implements its core strategy of 'full-process, integrated, internationalized, multi-therapy', driven by customer needs, deepening global presence, and strengthening technology platforms to achieve sustained core business growth[11] - Non-recurring gains/losses for the reporting period are estimated at RMB 60 million to RMB 70 million, a significant year-over-year decrease of approximately RMB 580 million compared to RMB 647.5201 million in the prior period (primarily from the disposal of PROTEOLOGIX, INC. equity), which is the main reason for the decline in net profit attributable to shareholders[11] - Despite the decline in net profit attributable to shareholders, core operating indicators show strong performance, with Q2 2025 operating revenue growing by 13.11%, net profit excluding non-recurring gains/losses by 23.33%, and adjusted non-IFRS net profit by 13.67% based on the forecast median[11] Other Relevant Information The company advises investors that this performance forecast is a preliminary, unaudited estimate by the finance department, with detailed financial data to be disclosed in the 2025 half-year report on the Shenzhen and Hong Kong stock exchanges, urging caution regarding investment risks - This performance forecast data represents a preliminary, unaudited estimate by the company's finance department[13] - Detailed H1 2025 performance data will be disclosed in the official reports published by the company on the Shenzhen Stock Exchange and Hong Kong Stock Exchange[14] Reference Documents Reference documents for this announcement include the Board of Directors' explanation regarding the performance forecast and other documents required by the Shenzhen Stock Exchange - Reference documents include: - Board of Directors' explanation regarding the current period's performance forecast - Other documents required by the Shenzhen Stock Exchange[15]